Gilead Sciences, Inc. (NASDAQ:GILD) – Oppenheimer Holdings issued their Q3 2017 earnings estimates for Gilead Sciences in a research report issued to clients and investors on Wednesday. Oppenheimer Holdings analyst H. Singh expects that the biopharmaceutical company will post earnings of $2.10 per share for the quarter. Oppenheimer Holdings currently has a “Market Perform” rating on the stock. Oppenheimer Holdings also issued estimates for Gilead Sciences’ Q4 2017 earnings at $1.85 EPS, FY2019 earnings at $7.23 EPS and FY2020 earnings at $7.37 EPS.
A number of other research firms also recently issued reports on GILD. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. Vetr raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 target price on the stock in a research report on Wednesday, September 6th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $83.00 target price (up previously from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th. Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Thursday, July 27th. Finally, ValuEngine downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 13th. Twelve equities research analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $85.66.
WARNING: This report was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://stocknewstimes.com/2017/10/11/gilead-sciences-inc-gild-to-post-q3-2017-earnings-of-2-10-per-share-oppenheimer-holdings-forecasts.html.
Shares of Gilead Sciences (GILD) opened at 83.04 on Monday. The company has a market cap of $108.44 billion, a P/E ratio of 9.02 and a beta of 1.14. The stock’s 50 day moving average price is $81.55 and its 200 day moving average price is $71.93. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $86.27.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm’s revenue was down 8.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.08 EPS.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Parnassus Investments CA increased its stake in Gilead Sciences by 37.4% in the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after buying an additional 4,556,901 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Gilead Sciences by 9.8% in the 1st quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock valued at $2,076,368,000 after buying an additional 2,727,063 shares during the last quarter. Renaissance Technologies LLC increased its stake in Gilead Sciences by 35.0% in the 2nd quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock valued at $736,667,000 after buying an additional 2,700,600 shares during the last quarter. Vanguard Group Inc. increased its stake in Gilead Sciences by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after buying an additional 2,148,697 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in Gilead Sciences by 50.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 6,191,622 shares of the biopharmaceutical company’s stock valued at $438,244,000 after buying an additional 2,062,886 shares during the last quarter. Institutional investors own 73.98% of the company’s stock.
In related news, EVP Gregg H. Alton sold 25,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $82.65, for a total value of $2,066,250.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the completion of the sale, the insider now owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The disclosure for this sale can be found here. Insiders sold a total of 486,819 shares of company stock worth $39,298,919 in the last 90 days. 1.30% of the stock is currently owned by company insiders.
The firm also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were issued a $0.52 dividend. The ex-dividend date was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.50%. Gilead Sciences’s dividend payout ratio is presently 22.58%.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.